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Abstract
Human colorectal cancers (CRCs) display a large number of genetic and epigenetic alterations, some
of which are causally involved in tumorigenesis (drivers) and others that have little functional impact
(passengers). To help distinguish between these two classes of alterations, we used a transposon-
based genetic screen in mice to identify candidate genes for CRC. Mice harboring mutagenic Sleeping
Beauty (SB) transposons were crossed to mice expressing SB transposase in gastrointestinal tract
epithelium. Most of the offspring developed intestinal lesions including intraepithelial neoplasia,
adenomas, and adenocarcinomas. Analysis of over 16,000 transposon insertions identified 77
candidate CRC genes, 60 of which are mutated and/or dysregulated in human CRC and thus are most
likely to drive tumorigenesis. These genes include APC, PTEN and SMAD4. The screen also
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identified 17 new candidate genes that had not previously been implicated in CRC, including POLI,
PTPRK, and RSPO2.
Recent genomic studies have revealed that human colorectal cancers (CRCs) undergo
numerous genetic and epigenetic alterations (1–4). These alterations likely derive from a
mixture of “drivers” that play a causal role in tumor formation and progression, and
“passengers” that have little or no effect on tumor growth. The design of targeted therapeutics
for CRCs is dependent on the ability to distinguish drivers from passengers.
To help identify potential driver genes in CRC we developed a forward genetic screen in mice
by using a Sleeping Beauty (SB) system for generating insertional mutations. To confine
transposition to the gastrointestinal tract, SB11 transposase cDNA preceded by a LoxP-flanked
stop cassette, was knocked into the Rosa26 locus (fig. S1) (5). These mice were then crossed
with Villin-Cre transgenic mice to activate SB transposase in epithelial cells of the
gastrointestinal tract (6). Once expressed, SB transposase catalyzed the transposition of T2/
Onc, a mutagenic SB transposon (7) (Fig. 1A). T2/Onc contains a murine stem cell virus long
terminal repeat and splice donor site (MSCV-LTR-SD), which can deregulate the expression
of a nearby proto-oncogene. T2/Onc also carries splice acceptor sites in both DNA strands and
a bidirectional poly(A) signal, which can inactivate the expression of a tumor suppressor gene.
Since SB transposition is biased toward reintegration of the transposon into the same
chromosome as the donor transposon – a phenomenon referred to as “local hopping” – we used
two T2/Onc transgenic lines that each carried approximately 25 copies of the T2/Onc
transposon in a concatamer on different donor chromosomes (Chr 1 and 15) (7).
A histochemical analysis of the triple transgenic mice (Rosa26-LsL-SB11, T2/Onc, Villin-
Cre) showed that SB transposase was strongly expressed in epithelial cells of the gut and
pancreas, but undetectable in other tissues (fig. S2). We created a cohort of 28 triple transgenic
mice and 72 double transgenic control mice carrying all possible dual combinations of the three
transgenes. Mice in this first cohort were monitored daily for 18 months. We generated a second
cohort of 50 triple transgenic mice that were maintained in a separate facility for 12 months
and also monitored daily.
Triple transgenic mice became moribund at a faster rate than double transgenic controls,
beginning around one year of age (Fig. 1B). Examination of the gastrointestinal tract of
moribund animals revealed discrete raised lesions from 2 mms to as large as 5 mms in diameter
in the small and large intestine. In the first cohort, 100% (12/12) of the experimental mice that
became moribund before 18 months harbored intestinal lesions (table S1), while none of the
control mice sacrificed before 18 months had lesions. In the second cohort, 72% (36/50) of
triple transgenic mice had intestinal lesions, with an average of 1.9 intestinal lesions in the
small intestines and 0.2 lesions in the large intestine.
We performed histopathologic analyses of tumor tissue sections from 11 animals. These
analyses identified 39 and 16 intraepithelial neoplasias, 50 and 15 adenomas and 3 and 0
adeocarcinomas in the small and large intestines, respectively (Fig. 1C–E). An additional
adenocarcinoma was identified for which the site of origin was undetermined. We also selected
six large tumors (≥ 5 mms) from six additional mice and found three were adenocarcinomas
and three were adenomas.
For use in DNA isolation and sequencing experiments, we harvested 135 tumors: 42 tumors
from 11 of the triple transgenic mice from the first cohort (dataset 1) and 93 tumors from 36
mice in the second cohort (dataset 2). The majority of tumors were small and the entire tumor
was used for DNA isolation. This precluded our ability to perform histological analysis and to
link the molecular data to the histopathology of specific tumors. However, given the
Starr et al. Page 2
Science. Author manuscript; available in PMC 2009 September 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
distribution of frank intestinal lesions from the histopathological analysis, the majority of
tumors were likely to be adenomas. We then performed linker-mediated PCR on DNA from
these 135 harvested tumors to generate PCR products containing transposon-genomic junction
fragments. We sequenced over 195,000 of these PCR products, of which 99,624 could be
uniquely mapped to TA dinucleotides in the mouse genome, consistent with SB insertion-site
requirements. After combining duplicate insertions within a given tumor, we found that 45%
of the insertions mapped to the same chromosome as the donor concatamer (Chr 1 or 15),
consistent with local hopping seen in previous SB screens. We removed these insertions from
further analysis to eliminate statistical bias due to local hopping. We also eliminated insertions
mapping to the precise TA dinucleotide in tumors from two or more different mice because
these insertions could represent a PCR artifact. The consummate total of 16,690 mapped, non-
redundant genomic loci (table S2) equates to an average of 124 mapped insertions per tumor.
To define common insertion sites (CISs), we performed Monte Carlo simulations using
randomly assigned insertions. Genomic window sizes were chosen based on simulations that
used the same number of insertions as the datasets, such that one would not expect to find a
single CIS after randomly distributing transposon insertions throughout the genome (Expected
value, E < 1). For example, in a random assignment of 16,690 insertions we would not expect
to find a single cluster of five insertions within 25 Kb, six insertions within 50 Kb, seven
insertions within 80 Kb, etc. (8). Any cluster of insertions meeting or exceeding these
parameters was defined as a CIS. We removed one CIS from this list because it was composed
entirely of insertions from a single mouse, indicating that those tumors may be related.
As a final control, we amplified and sequenced 15,556 SB insertions present in tail DNA
derived from 89 double transgenic weanling mice. These mice contained a ubiquitously
expressed SB11 transposase transgene and the T2/Onc transposon concatamers (7,9). Because
there was no selection pressure for tumor outgrowth in these mice and because SB integration
does not have a strong bias for any individual TA dinucleotide (10), we expected the insertions
to be distributed randomly throughout the genome, except for local hopping. From this control
dataset we identified six CISs. This was more than expected, but considerably less than that
observed in tumor DNA (table S3). These CISs could be previously unknown hotspots for
transposon integration. Alternatively, they could reflect incipient clonal neoplastic growth, as
these genetically manipulated mice eventually develop lymphoma (9). Two of these six CISs
were also identified in the tumor datasets, thus they were eliminated from the list of tumor
CISs, leaving us with 77 CISs (table S4).
Candidate genes were assigned to the 77 CISs according to the percentage of insertions in or
near a gene within the CIS boundaries. Insertions were mainly located within introns (51%),
with only 2% in an exon and the remaining 47% either upstream or downstream of a coding
region. The top 10 CISs, based on number of insertions found, are listed in Table 1.
The goal of this study was to identify genes that are drivers of tumorigenesis in order to identify
new candidate genes whose mutational status in human CRC can then be tested. We compared
our list of mouse CIS genes to the human genes listed in the Catalog of Somatic Mutations in
Cancer (COSMIC) database (11). Among our list of 77 CIS genes, 38 have human homologs
present in the COSMIC database, and 18 (47%) of these 38 homologs have documented non-
silent mutations in human cancers (table S5), which would not be expected by chance (P <
0.05). Furthermore, if we limit our analysis of COSMIC to genes mutated in human CRC, the
overlap has a lower probability of being due to chance (p < 0.001) (8).
Similarly, our CIS list overlaps with a recent large-scale exon-resequencing project that
cataloged mutations in 18,191 human genes in 11 colorectal tumor samples (1). That project
identified 848 human gene mutations, 140 of which were considered likely to be driver
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mutations for CRC. Of the 77 CIS mouse genes identified in our study, 74 have human
homologs that were included in the exon-resequencing study. Among these 74 homologs, 10
had a mutation and four were identified as candidate driver mutations in human CRC (table
S6) making these findings highly significant (p < 0.005) (8).
We then investigated whether the human homologs of the mouse CIS genes were amplified or
deleted in human CRC. We examined a dataset that identified 482 deletions and 224
amplifications in human CRCs (8). The human homologs of 10 CIS genes were located in
deleted regions and 23 were located in amplified regions (table S7 & table S8). This represents
a significant overlap (p < 0.05) (8) and suggests that the candidates found in this screen are
relevant to human CRC.
Finally, we analyzed cDNA microarray data to determine whether CIS genes were
differentially expressed in human CRC versus normal colonic tissue. The Oncomine database
(12) contains five microarray datasets that compare gene expression levels in 138 CRCs and
88 normal samples. Of the 77 CIS human homologs, 50 were identified as being differentially
regulated (p < 0.05) in one or more of these studies (table S9).
By comparing our list of mouse CIS genes with human genes that are (i) mutated in CRC, (ii)
listed in COSMIC, (iii) amplified or deleted in CRC, (iv) aberrantly expressed in CRC or (v)
known cancer genes identified by the Cancer Genome Project (CGP) (13), we identified 15
CIS genes that are the most likely to be driver mutations in human CRC (Table 2) by virtue of
being present in at least three of the five categories listed above. Among these 15 genes is
adenomatous polyposis coli, Apc, a member of the Wnt signaling pathway and the most
commonly mutated gene in human CRC (70–80%) (14). Also included in this list are
Bmpr1a, Smad4, and Pten, which are responsible for juvenile polyposis syndrome, juvenile
intestinal polyposis, and Cowden disease, respectively. Another gene on the list, Fbxw7, is a
component of the SCF ubiquitin ligase complex, which is mutated in 11.5% of human CRCs
(15). Thus, among the 15 prioritized genes in our study, five are validated human CRC genes
and together represent some of the most commonly mutated genes identified in human CRC.
Three other genes on the complete CIS list (table S4) are also implicated in human CRC:
CDK8, MCC and SND1. CDK8, which encodes cell division protein kinase 8, is commonly
amplified in human CRC and plays a direct role in β-catenin-driven cell transformation (16).
MCC encodes the colorectal mutant cancer protein and, in addition to finding somatic mutations
in MCC (17), a recent study found that 50% of primary CRCs exhibited MCC promoter
methylation (18). Furthermore, MCC interacts with β-catenin and its re-expression in CRC
cells inhibits Wnt signaling and proliferation, suggesting that MCC is a tumor suppressor
(19). SND1, a component of the RNA-induced silencing complex, is highly expressed in CRC
and its overexpression in rat epithelial cells leads to a loss of contact inhibition and increased
cell growth (20). Interestingly, SND1 overexpression leads to a downregulation of APC protein
even though mRNA levels are unchanged.
In addition to identifying genes whose human homologs are known to be altered in cancer, our
screen identified a number of novel candidate CRC genes that could, on the basis of their
function, be drivers of CRC. These candidate CRC genes include POLI, PPP1R13B, and
RSPO2, which affect DNA stability, p53-induced apoptosis, and Wnt signaling, respectively.
POLI, the product of POLI, is an error-prone DNA polymerase responsible for the high
frequency of UV-induced mutations in xeroderma pigmentosum variant cells (21). PPP1R13B,
the product of PPP1R13B, enhances the ability of p53 to stimulate the expression of pro-
apoptotic genes (22). RSPO2 is a member of a novel family of Wnt-signaling regulators, the
R-Spondins (23). Finally, two microRNA genes not previously associated with CRC,
Mirn181b-2 and Mirn181a-2, reside within an intron of Nr6a1, one of the CIS genes identified
Starr et al. Page 4
Science. Author manuscript; available in PMC 2009 September 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
in our screen. It is possible that these microRNAs, and not the gene Nr6a1, are the genes
affected at this CIS. Both of these microRNAs are aberrantly expressed in CRC (24,25) and
function as tumor suppressors in glioma (26).
Our transposon-based forward genetic screen encountered some limitations. We believe the
screen was unable to recapitulate the effect of certain activating point mutations, such as the
KrasG12V mutation that is found in a large percentage of CRC. In addition, random transposon
insertions could potentially miss small genetic loci such as microRNAs. By design, the
statistical method we used to determine CISs in order to identify likely candidate driver
mutations ignores the majority of mapped transposon insertions that occurred in only one or
two tumors. These non-CIS insertions may also have contributed to carcinogenesis by creating
CRC driver or cooperating mutations or by causing some other level of genomic instability.
In summary, our transposon-mediated forward genetic screen in mice identified genetic
mutations that lead to the development of an epithelial cancer. The discovery of a significant
overlap of mouse candidate genes and human genes that are altered in cancer indicates that
this mouse model will be useful for distinguishing between driver and passenger mutations. In
addition, the large number of CISs uncovered in this screen affirms the hypothesis that the
growth of human CRC is driven by a few commonly mutated genes and a much larger number
of genes that are rarely mutated (1).
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Fig. 1.
Triple transgenic mice develop intestinal tumors and become moribund faster than double
transgenic controls. (A) Breeding scheme for generating triple transgenics. (B) Kaplan-Meier
Survival curve comparing triple transgenics to double transgenic controls. Photomicrographs
of hematoxylin and eosin stained representative tissue showing an adenoma (C), an
adenocarcinoma (D) with arrow pointing to a cluster of glands that has invaded through the
serosa, and gastrointestinal intraepithelial neoplasia (E) with arrow indicating a cluster of
dysplastic glands accompanied by fusion of villi. Vil = Villin promoter, RLS = Rosa26-Lox-
stop-Lox-Sleeping Beauty 11, Tg = Transgenic, bars = 250 µm (C), 500 µm (D), and 100 µm
(E).
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Table 1
Top 10 CIS candidate genes, ranked according to the number of unique insertions defining the CIS
Candidate Gene Chromosome # of unique insertions Function
Apc 18 61 Wnt signaling
Rspo2 15 17 Wnt signaling
Kcnq1 7 14 Potassium channels
Tcf12 9 13 Transcription factor
Wac 18 13 Novel adaptor
Fbxw7 3 11 Ubiquitination
Ptprk 10 11 Cell adhesion
Cugbp1 2 10 RNA binding
Nr6a1 2 10 Orphan nuclear receptor
Zcchc7 4 10 Novel zinc finger
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Table 2
Candidate CIS genes likely to be drivers of human CRC
Gene Symbol Mutated in human
cancer*
Amplified or deleted
in human CRC†
Aberrantly expressed
in human CRC‡
Known human
cancer gene§
ANKRD11 x x x
APC x x x
BMPR1A x x x x
DSTN x x x
EVI1 x x x
FBXW7 x x
GPBP1 x x x
NOTCH1 x x x x
NSD1 x x x
PPP1R12A x x
PTEN x x x x
RREB1 x x x
SMAD4 x x x x
TCF12 x x x x
TNPO3 x x x
*
A somatic mutation was identified in COSMIC or by exon-resequencing of human CRCs by Wood et. al., (2).
†
Gene is located in a region known to be deleted or amplified in human CRC.
‡
mRNA level was significantly different (p < 0.05) in human CRC compared to normal colon tissue.
§
Gene is identified as a human cancer gene by the Cancer Genome Project (13).
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